Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MEXT to Support Establishment of “Open Innovation Organizations” at Universities
April 6, 2018
- Invest in DNA-Based Prevention for Cancer, Dementia and Other Technological Innovation: CEFP Member
April 5, 2018
- MHLW Panel to Kick Off Debates on Amendment of Pharmaceuticals and Medical Devices Law
April 5, 2018
- PMDA Announces Report Outlining “Current Views” on Introduction of Continuous Manufacturing
April 5, 2018
- Ono Takes over Orphan Designation for 2 Products Including MEK Inhibitor from Array BioPharma
April 4, 2018
- MHLW to Discuss Stockpiling of Xofluza, Tamiflu Generics in FY2018
April 3, 2018
- Use of Big Data Entering New Stage with Launch of MID-NET, Enforcement of New Law
April 3, 2018
- AMED Out-Licenses 2 Compounds in Drug Discovery Support Initiative
April 2, 2018
- Chuikyo Begins Debate on Sales Tax Hike, Agrees on Drug Price Survey in 2018
April 2, 2018
- MHLW Orders Package Insert Revisions for Antibacterial Drugs
March 29, 2018
- Sakigake Status Goes to World’s 1st Renal-Function Improving Agent, BBB-Penetrating Hunter Syndrome Med and 4 More Drugs
March 28, 2018
- MHLW’s Panel to Discuss First Revision of Anti-RA Measures in 7 Years; Proper Use of Biologics to Be a Focus
March 28, 2018
- Council OKs Public Knowledge-Based Application for Elplat Triplet
March 26, 2018
- MHLW Approves Hemlibra, Shingrix, Ozempic, and More
March 26, 2018
- 16 Possible Topics for New Guidelines Including Continuous Manufacturing to Be Discussed at First ICH “Interim Meeting” this Week
March 26, 2018
- Gilteritinib, 3 Other APIs Earn Orphan Designation
March 23, 2018
- MHLW to Purchase, Stockpile Enough Inavir for 3.81 Million People, Avigan for 1.91 Million People
March 23, 2018
- MHLW Orders Label Revisions for Samsca Acute Liver Failure Added to Significant ADR List
March 22, 2018
- Healthcare Experts at Odds over Nonprescription Switches of 3 PPIs
March 20, 2018
- Price Adjustments Based on Cost-Effective Assessments “Impossible”: Prof. Sakamaki
March 20, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…